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ABSTRACT
Introduction: Since 2007, many countries have
implemented national human papillomavirus
(HPV) vaccination programs with the
quadrivalent HPV (4HPV) vaccine that has
been shown to be efficacious in clinical trials
involving 25,000 subjects. Two vaccine
serotypes, HPV16 and 18, are responsible for
cervical cancer and other HPV-related cancers,
but the impact of the 4HPV vaccine on these
cancers cannot be seen immediately as there is a
considerable lag between infection with HPV
and cancer development. The other two
serotypes, HPV6 and 11, are responsible for
genital warts (GWs), which develop within a
few months after infection, making GWs an
early clinical endpoint for the assessment of the
impact of 4HPV vaccination.
Methods: We performed a systematic literature
search in PubMed to identify all published
studies on 4HPV vaccination, including those
that assessed the impact of 4HPV vaccination
programs on the incidence of GWs at a
population level around the world.
Results: A total of 354 records were identified
in the PubMed search. After screening and
obtaining full papers for 56 publications, 16
publications presenting data on the impact or
effectiveness of 4HPV vaccination on GWs were
identified. These reported data on the impact or
effectiveness of 4HPV in six countries [Australia
(n = 6), New Zealand (n = 2), United States
(n = 3), Denmark (n = 2), Germany (n = 1),
and Sweden (n = 2)]. In Australia, no GWs
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were diagnosed in women aged \21 years who
reported being vaccinated. A 92.6% reduction
in GWs incidence was reported for all women in
this age group, where the vaccine uptake rate
(VUR) was 70% for 3 doses. The highest
reductions were reported in countries with
high VURs, mostly through school-based
vaccination programs, although high VURs
were obtained with some non-school-based
programs.
Conclusion: The results are coherent with the
GWs incidence reduction reported in clinical
trials and are an early indicator of what can be
expected for the long-term clinical impact on
vaccine-type HPV-related cancers.
Keywords: 4HPV vaccine; Gardasil; Genital
warts; Human papillomavirus; Quadrivalent
human papillomavirus vaccine; Vaccine
effectiveness; Vaccine impact
INTRODUCTION
Genital warts (GWs) are a sexually transmitted
disease caused by human papillomavirus (HPV)
and are the most common sexually transmitted
disease in some countries [1, 2]. HPV6 and
HPV11 are responsible for about 90% of the
cases of GWs [3]. Worldwide, several million
cases of GWs occur each year in both sexes, with
a peak incidence between 20 and 24 years of age
for females and between 25 and 29 years among
males [4].
Genital warts usually occur about
6–12 months after the first infection with HPV
[5]. However, in the placebo arms of two large
randomized clinical trials assessing the
quadrivalent HPV (4HPV) vaccine, the delay
between PCR detection of HPV DNA and the
occurrence of GWs was variable and could be as
long as 2 years [3]. Data from the placebo group
of these clinical trials show that GWs can
spontaneously regress in up to 40% of cases
[3]. Although GWs are not life-threatening, they
are often associated with considerable psycho-
sexual distress and represent an important
financial and resource burden for the health
system [6]. The estimates for the unit cost for a
single GWs event are highly variable,
depending on the type of episode (first
occurrence, recurrent or persistent GWs), the
management setting and type of consultation
[general practice, genitourinary medicine
(GUM), hospital, etc.], as well as the therapy
used (medical treatment vs. surgery or other
modalities) [7, 8]. A recent study in Italy
reported that the most frequent cause for
HPV-related hospitalization was GWs [9]. An
economic analysis showed that the costs
associated with GWs in men and females
represented 24.3% (€70.9 million) of the total
costs associated with HPV6/11/16/18 diseases in
Italy. Most of the costs for 4HPV vaccination
would have been covered by the prevention of
GWs and the associated costs alone [10].
Two recombinant, virus-like particle (VLP)-
based prophylactic HPV vaccines are currently
available. One is a bivalent (2HPV) vaccine
licensed for the prevention of premalignant
cervical, vulvar and vaginal lesions and cervical
cancer causally related to HPV16 or HPV18 in
females. The other is a quadrivalent (4HPV)
vaccine also licensed for the prevention of
premalignant cervical, anal, vulvar and vaginal
lesions and cervical and anal cancer related to
HPV16 or HPV18. In addition, 4HPV is licensed
for the prevention of GWs caused by HPV6 or
HPV11 in both men and females [11].
Since 2006–2007, HPV vaccines have been
licensed in over 133 countries and introduced
into national immunization programs in at
least 40 countries [12]. Over 169 million doses
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of 4HPV have been distributed worldwide since
its launch.
In the FUTURE I and II randomized clinical
trials, 4HPV vaccine was shown to reduce the
incidence of HPV6- and HPV11-related GWs in
females aged between 15 and 26 years by 99% in
a per-protocol susceptible population (females
who were seronegative on day 1 and DNA
negative on day 1 through month 7 to the
respective HPV type, who received three doses
of vaccine) [13]. A reduction of 62% was
reported in an intent-to-treat population
(females with past or current HPV exposure
and those naı¨ve to HPV who received[1 dose of
vaccine) [13].
In countries that have implemented national
vaccination programs against HPV, health
economics models have estimated that the
impact of these programs will only be seen for
cervical cancer and other HPV-related cancers,
at the population level, 30–50 years after the
initiation of the vaccination program, due to
the generally long time lag between infection
and cancer [14, 15]. However, since HPV-related
GWs develop rapidly after HPV infection, with a
peak incidence between 20 and 35 years of age,
the vaccine impact on their incidence should be
visible earlier.
It is important to survey the impact of any
new vaccine. Although some registries and
surveillance systems have been set up to
monitor the impact of 4HPV vaccination on
cervical cancer and other HPV-related diseases,
they are heterogeneous and not implemented
everywhere. In addition, these diseases, which
take a certain time to develop, will only occur a
long time after vaccine programs have been
implemented. Since the impact of HPV
vaccination on GWs will be seen earlier, the
surveillance of their incidence and prevalence is
a good indicator of the impact of vaccination
on other vaccine-related HPV diseases and
cancers. Data on the incidence and prevalence
of GWs will not be available for all countries, as
GWs are not a notifiable disease everywhere.
However, some data can be obtained through
sentinel surveillance systems for sexually
transmitted infections or through the
implementation of national networks using a
sample of first-level ‘sentinel’ general
practitioners or gynecologists, as has been
done in Italy [16, 17]. Nevertheless, assessing
the impact of HPV vaccination in a reliable and
robust manner is easier in countries that have
good surveillance systems for GW, e.g. United
Kingdom (UK), Australia, and the Nordic
countries.
The aim of the present review article is to
summarize the published data reporting the early
impact of HPV vaccination on GWs in countries
that have introduced 4HPV into their national
immunization programs. We specifically looked
at countries where the 4HPV vaccine is
recommended, either exclusively or not, since
this is the only available vaccine licensed for the
prevention of GWs via HPV6 and HPV11
included in the vaccine [11].
METHODS
As part of ongoing literature surveillance for
publications on 4HPV, we had identified a
number of studies assessing the impact of
4HPV vaccination programs on GWs. To verify
that all the relevant studies had been identified,
we performed a systematic literature search in
PubMed from January 1, 2009 to August 21,
2014, using a combination of the following
terms: papillomavirus; condylomata acuminata
anogenital warts; genital warts; incidence;
mass vaccination; vaccination methods;
immunization/immunisation; real life;
papillomavirus vaccines; HPV vaccine
effectiveness; HPV vaccine impact; HPV
12 Adv Ther (2015) 32:10–30
vaccination; ecological study HPV; reduction;
impact; insurance claim review; military
personnel, as free-text or MeSH terms.
Studies were eligible for inclusion in this
review if they reported population-based data of
vaccine impact. In addition, the 4HPV vaccine
had to be included in the national
immunization program; the publication had to
report results from ecological studies of vaccine
impact on GWs for defined pre- and post-
vaccination periods; and the post-vaccination
period had to start at least 1 year after the HPV
vaccination program started. Publications
reporting results for the same cohort at
different post-vaccination periods were kept to
assess the trends over time.
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
A total of 354 records (after removal of
duplicates) were identified in the PubMed
search. After a first screen on titles and
abstracts, full papers for 56 publications were
analyzed and 16 publications presenting data on
the impact or effectiveness of 4HPV vaccination
on GWs were identified (Fig. 1). These reported
data on the impact or effectiveness of 4HPV in 6
countries [Australia (n = 6) [18–23], New
Zealand (n = 2) [24, 25], US (n = 3) [26–28],
Denmark (n = 2) [29, 30], Germany (n = 1) [31]
and Sweden (n = 2) [32, 33]] (Table 1). Since
both impact and effectiveness publications
assess the effect of vaccination programs on
the incidence of the disease, both types of
studies have been included. Fourteen of the
studies used a before/after design or evolution
over time to assess the change in GWs episodes
after 4HPV vaccine introduction; two studies
compared GWs in vaccinated and unvaccinated
cohorts (Table 1).
The studies included in this review were
performed in settings where the 4HPV vaccine
was either the only vaccine available or it was
used in[90% of the vaccinated population. The
estimated vaccine uptake rates for C1 dose
varied between the studies, from 25% in
Sweden to 90% in Denmark (Table 1).
Some of the studies also reported that the
incidence of GWs in men who have sex with
men (MSM) was stable during the studied
period [18, 20, 21]. Two studies reported that
the incidence of other sexually transmitted
diseases, chlamydia and genital herpes,
increased or remained stable over studied
period [18, 27].
In this review, we present data for the direct
impact/effectiveness in vaccinated cohorts. We
also present data for the indirect impact, or herd
protection, in the unvaccinated population,
since this contributes to the overall impact of
the vaccine. The unvaccinated population has
been divided further:
• Heterosexual men of a similar age who could
have sex with vaccinated females and
therefore could be expected to benefit from
herd protection;
• Older females who are less likely to be
vaccinated and older heterosexual men
who are less likely to benefit from herd
protection;
• MSM who are unlikely to have sex with
vaccinated females, and at the time of the
studies, male vaccination had not been
recommended.
Due to the diversity of the study designs, the
HPV vaccination programs and vaccine uptake
rates, the results are presented country by
country.
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Australia
Australia was one of the first countries to
implement a fully funded national population-
based 4HPV vaccination program in April 2007.
The program provided free vaccination for
females aged 12–13 years in schools. In
addition, from July 2007 to December 2009
there was a catch-up program for females aged
13–18 years and another for females aged
18–26 years in the community. Since 2013, the
vaccine program has been extended to males
aged between 12 and 13 years. In 2007, it was
estimated that vaccine uptake in eligible school-
aged females was 70%; by 2011, approximately
80% had received one dose of vaccine and 70%
had received three doses [34]. We identified two
publications that reported data from the
Melbourne Sexual Health Centre 1 year (2008)
and 4 years (2011) after 4HPV introduction [20,
21] and two that reported data from eight
Sexual Health Centers throughout Australia
2 years (2009) and 4 years (2011) after 4HPV
introduction [18, 19] (Table 1). In addition, we
identified one study comparing national
population surveys on GWs in 2001 and 2011
and another that analyzed national hospital
data for GWs [22, 23].
In the first report from Melbourne, the years
analyzed were from January 2004 to December
2008 whereas in the later report they were from
July 2004 to June 2011 [20, 21]. In addition, the
subgroups analyzed were different. Despite
these differences, rapid and significant declines
Fig. 1 PRISMA ﬂowchart summarizing the results from the PubMed search. 4HPV Quadrivalent HPV, GW Genital warts,
HPV Human papillomavirus
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in the percentage of females and heterosexual
men aged\30 years presenting with GWs were
reported. In females aged\28 years, the
percentage decreased 52.0%, from 12.7% in
2004–2007 to 6.6% in 2008, 1 year after
vaccine introduction. From July 2010 to June
2011, 4 years after vaccine introduction, the
percentages of females aged\21 years and
21–29 years with GWs were 1.9% and 3.7%,
respectively. No decline was observed for
females and heterosexual men
aged C30 years, for MSM or for non-residents
(who were not eligible for the 4HPV
vaccination program).
The first report from the national study,
involving eight sexual health services,
including the Melbourne service, revealed a
significant decrease of 59% [95% confidence
interval (CI) 54–61%] for 4HPV-eligible females
aged 12–26 years with GWs, from 11.7% in July
to December 2007 to 4.8% in July to December
2009, 2 years after vaccine introduction. There
was also a significant 39% (95% CI 33–46%)
decrease for heterosexual men aged 12–26 years
with GWs, in the same period [19]. No
significant reductions were seen for non-
resident females of eligible age, females and
heterosexual men aged[26 years or MSM. The
second report from this study, reporting data for
up to 4 years after 4HPV vaccine introduction,
showed a further decrease up to 92.6% in the
percentage of females aged\21 years with GWs,
from 11.5% in 2007 to 0.85% (i.e., 13 cases) in
2011 [18]. None of the 235 females
aged\21 years who had been vaccinated were
diagnosed with GWs. In females aged
21–30 years there was a 72.6% reduction of
GWs, from 11.3% in 2007 to 3.1% in 2011. This
study also confirmed the significant reduction
of GWs in heterosexual men aged B30 years
while confirming the absence of impact on
older females, older heterosexual men and
MSM. The decline in GWs contrasted with the
increase in chlamydia infections and no change
in genital herpes infections, over the same
period. The comparison of national
population-based surveys in 2001 and 2011
confirmed the decline in GWs and the
increase in chlamydia infections [23]. The
analysis of Australian national hospital data
between 1999 and 2011 confirmed the
reduction of GWs in young females and also
in young men (herd protection), with a similar
impact in indigenous and non-indigenous
populations [22].
New Zealand
The 4HPV vaccine was introduced in New
Zealand in September 2008 for females in year
8 (aged 11–12 years), with a catch-up program
for females born after January 1, 1990 until the
end of 2010. The estimated vaccine uptake rate
in eligible females was 51.7% in 2009 for the
Auckland District Health Board [24].
A retrospective study of new patients with
GWs attending the Auckland Sexual Health
Service between January 2007 and June 2010
showed a statistically significant reduction of
62.8% in females aged\20 years with GWs,
from 13.7% in 2007 to 5.1% in 2010 and a
reduction of 21.3% in females aged[20 years,
from 7.5% in 2007 to 5.9% in 2010 (Table 1)
[24]. A similar, but statistically non-significant,
reduction was observed in young males.
Another study used a prescription database
(PHARMAC) to assess the impact on
prescriptions for GW treatments (imiquimod
and podophyllum) and as a surrogate outcome
for GWs [25]. They reported the largest decrease
in prescriptions in females aged under 20 years
(Table 1).
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United States
The 4HPV vaccine was introduced in the
United States (US) in June 2006 for females
aged 11–12 years with catch-up for those aged
13–26 years; in 2011, the recommendations
were extended to males aged 11–12 years
with catch-up for those aged 13–21 years [35,
36]. The uptake rate for C1 dose among
adolescents aged 13–17 years in 2010 varied
from 22.5% in the US Virgin Islands to 73.0%
in Rhode Island with a national average of
48.7% [37]. In females and males aged
19–26 years, the uptake was 20.7% and 0.6%,
respectively [38].
Three studies reported data showing the
impact of 4HPV vaccination on GWs [26–28].
One study included 64 million person-years of
data for subjects aged 10–39 years enrolled in
about 100 health insurance plans throughout
the US [27]. The results showed a significant
decline in the prevalence of GWs 4 years after
the introduction of 4HPV vaccination
(2006–2010), from 2.9 per 1,000 person-years
to 1.8 in females aged 15–19 years and from 5.4
to 4.8 in females aged 20–24 years. No decrease
was observed for older females. In males aged
20–24 years there was a significant increase
from 2.5 in 2003 to 5.0 in 2009 followed by a
significant decrease to 4.6 in 2010. The other
two studies were not national: one analyzed
data from the Californian Public Family
Planning Administrative Claims database and
the other analyzed data from the Defense
Medical Surveillance System, concerning US
service members during their military service
careers [26, 28]. The study in California reported
a 34.8% decrease (0.94–0.61%; Ptrend\0.001) in
GW diagnoses between 2007 and 2010 in
females aged\21 years. Decreases were also
reported in females aged 21–25 years (10.0%
decline; Ptrend\0.001), males aged\21 years
(18.6% decline; Ptrend\0.001), and males aged
21–25 years (11.2% decline; Ptrend\0.001) [26].
No change was reported for females or males
aged[30 years. The study on US service
members reported a marked decrease in the
annual incidence rate of GWs from 2007 to
2010 among females aged\25 years [28]. The
incidence rates of GWs remained relatively low
and stable in females aged C25 years and men of
all ages from 2000 to 2010, although there was
an increase for these subjects between 2010 and
2012.
Denmark
The 4HPV vaccine was licensed in Denmark in
October 2006 and since January 2009 it has
been offered free of charge to all females aged
12 years, with catch-up in females aged up to
15 years. In 2012, the 4HPV vaccine uptake
for C1 dose was between 87% and 90% and 82%
and 81% for three doses for the first two birth
cohorts and 85% in the catch-up campaign [29,
30].
Two studies that used data from the Danish
National Patient Register have been published
[29, 30]. The register contains information on
all hospitalizations and outpatient
consultations, including GWs. One study
reported the incidence of GWs in Denmark
and the other reported the effectiveness of
4HPV vaccination for preventing GWs [29,
30]. The greatest impact was reported for
females aged 16–17 years with a decrease from
381.5 per 100,000 in the second half of 2008 to
39.8 per 100,000 in the first half of 2011,
representing an average annual percentage
decrease of 45.3%. In other age groups there
was a significant but more gradual decrease
reported from 2009 [29]. There was a
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non-significant reduction in the incidence of
GWs in all age groups of men, with the greatest
reduction in those aged 22–25 years.
In the second study, all females in the
1989–1999 birth cohorts were identified and
information about their HPV vaccination status
was obtained for the period 2006–2012 [30]. In
this study 248,000 out of the 399,967 females
(62.2%) were vaccinated. After a median follow-
up of 3.1 and 3.5 years for the vaccinated and
unvaccinated females, respectively, the relative
risks of GWs in females who had received C1
dose of 4HPV compared with unvaccinated
females were 0.12 (0.04–0.36), 0.22
(0.15–0.33), 0.25 (0.19–0.32), and 0.62
(0.50–0.76) for those born in 1995–1996,
1993–1994, 1991–1992, and 1989–1990,
respectively (P for trend\0.0001). No GWs
occurred among vaccinated females in the
youngest birth cohort (1997–1999).
Germany
In Germany, HPV vaccination for the
prevention of cervical cancer was
recommended for females aged between 12
and 17 years in March 2007. Although the
type of vaccine was not specified in the
German Standing Vaccination Committee
(STIKO) recommendation, about 90% of the
doses sold in Germany were 4HPV. In
2008–2009, the vaccine uptake rate was about
40% in females aged 16–18 years [31].
Data from one large health insurance
company in Germany showed a reduction in
the incidence of anogenital warts in females
aged 16 (47%), 17 (45%), and 18 (35%) years at
the end of 2008, soon after the
recommendation for HPV vaccination [31].
There was no evidence of a reduction in
incidence in older females and males.
Sweden
From May 2007, 4HPV vaccine has been
available at a subsidized cost for females aged
13–17 years; vaccination was, therefore,
administered in clinics and costs were incurred
by the females or their parents. It was estimated
that 25% of females aged 13–20 years had
received C1 dose of 4HPV [32]. Vaccine uptake
rates were highest in those aged 18–19 years
(31.9%) and those aged 13–17 years (24.7%)
[33].
Two studies reported results from the
analysis of data extracted from the Swedish
Prescribed Drug and the National Patient
Registers to identify GW episodes in the
population aged between 10 and 44 years
between 2006 and 2010 [32, 33]. One of the
studies showed significant decreases in the
incidence of GWs in females aged 15–25 years
from 2006 to 2010 (P\0.001 test for trend); the
decrease was highest ([25%) in those aged 17
and 18, with significant decreases up to 25 years
[32]. No significant trends over time were
observed for males (P = 0.71 test for trend).
The second study reported a vaccine
effectiveness of 76% (95% CI 73–79%) among
females who received three doses of vaccine
with the first dose before 20 years [33]. The
effectiveness was highest in those vaccinated
before 14 years (93%) compared with 71%
between 17- and 19-year old and 48% between
20- and 22-year old.
DISCUSSION
This summary of published data provides
evidence that there is a rapid reduction in the
incidence of GWs after the implementation of
4HPV vaccination, at least, in the target
population, despite the differences in study
24 Adv Ther (2015) 32:10–30
designs, populations studied, and 4HPV vaccine
implementation and uptake. The results for the
trends of other sexually transmitted diseases
that increased or remained stable suggest that
the reduction in GW incidence is unlikely to be
explained by changes in sexual health
education or in sexual behavior [18, 29].
Results from the study in Sweden suggest
that vaccination at an early age results in higher
protection, with the highest effectiveness for
vaccination at 10–13 years [33]. The younger
the subjects are at vaccination, the less likely
they are to have been in contact with HPV, and
therefore, the more likely they will be protected
with a prophylactic vaccine such as 4HPV
vaccine.
The results from this review also provide
some evidence for possible herd protection in
unvaccinated populations of men and older
females, particularly in settings with high
vaccine uptake rates [18]. However, herd
protection was not seen in all countries (e.g.,
Denmark) suggesting that factors other than
vaccination, for example, population dynamics
could contribute to herd protection [29]. A
study in Australia using a national general
practice database, published after our literature
search had been done, reported a reduction of
61% in GW management rate in vaccine-
eligible females for the post-vaccination period
(July 2008–June 2012) but no change in older
females or in males of any age [39].The US
Centers for Disease Control and Prevention
reported that male HPV infections are
responsible for about one-third of the total
expected burden of HPV-associated cancers,
emphasizing how universal vaccination could
be beneficial by providing direct protection
[40]. Certain populations, such as MSM, will
not benefit from herd protection from a female
HPV vaccine program. Thus, it is reasonable to
consider universal HPV vaccination programs to
provide direct protection to all individuals,
irrespective of their gender [41]. Despite the
considerable indirect effects seen in Australia,
the Australian government has implemented a
publically funded program for 4HPV
vaccination in boys aged 12–13 years, with a
2-year catch-up program for boys aged
14–15 years [42]. In early 2014, Austria started
a vaccination program for both boys and
females [43, 44]. In the UK, the Joint
Committee on Vaccination and Immunization
is considering extending the HPV vaccination
program; a group of parliamentarians with a
special interest in public health published an
open letter in support of extending to the
program to males [45].
Although the 2HPV vaccine does not contain
HPV6 or HPV11, an unexpected result was
reported from an ecological study in the UK.
2HPV vaccination was introduced in September
2008 for females aged 12–13 years with catch-up
for those up to 18-year old. The vaccine uptake
was reported to be[80% in the routine cohorts
and about 40% or more in the oldest catch-up
cohorts [46]. It was reported that there were
reductions in diagnoses of GW in GUM clinics
of 13.3% in females aged 16–19 years from 2008
to 2011. The results from a recent analysis
suggested that the reported reduction in GW
diagnoses in the UK could be partially due to
the recent introduction of asymptomatic
screening pathways whereby testing for
sexually transmitted diseases is offered to
asymptomatic patients without an
examination by a clinician, leading to up to
12.3% of GWs being missed [47]. In addition, a
study performed between October 2010 and
June 2012 in the UK, using PCR-confirmed HPV,
reported that while there was a reduction in
HPV 16/18 infections in the post-vaccination
period, no such reductions were seen for HPV6/
11 infections in females aged 16–21 years [48].
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Another study in Scotland where the 2HPV
vaccine uptake was 91% also demonstrated that
while 2HPV vaccination significantly reduced
vaccine type and related type HPV infections,
there were no reductions in the prevalence of
HPV6/11 infections [49]. Results from ad hoc
analyses for persistent infection in samples
collected during the large randomized clinical
trial on 2HPV showed that the vaccine reduced
persistent infection with HPV6 by 34.9% in
females naı¨ve for all HPV types [50]. However,
no reduction was observed for HPV11 in this
population and no reduction was observed for
HPV6 or HPV11 in the total vaccinated
population comprising all subjects who had
received C1 dose of 2HPV, irrespective of their
HPV status at enrollment. An analysis of the
HPV types present in GWs in the placebo groups
of two randomized clinical trials of 4HPV
showed that while HPV6/11 were present in
86.0% (447/520) of the GWs analyzed in which
HPV was detected, HPV16/18 were also present
in 13.4% (64/478) of these lesion [3].
In September 2012, the UK switched to the
4HPV vaccine in their program. Due to direct
protection against HPV 6 and 11 conferred by
4HPV, greater reductions in the incidence of
GWs are expected to be observed; and this will
also accompanied by reductions in HPV6 and
HPV11 infections. In the US, 4 years after 4HPV
vaccine introduction, in females aged
14–19 years, a decline of 56% (11.5–5.1%) of
vaccine-type HPV infection was reported
despite a low vaccine uptake rate; vaccine
effectiveness for C1 dose was estimated to be
82% [51]. In Germany, where the vaccine
uptake is also low, a similar decline of 54.5%
(22.4–10.2%) in HPV16/18 infections has been
reported in females aged 20–21 years [52].
Recently in Belgium, the results from a
retrospective study between September 2009
and January 2012 in females aged 15–19 and
20–24 years showed a significant decrease in
HPV 16 infection in the younger age group,
with a similar-sized reduction for HPV18, which
was not significant [53]. In the older age group,
where HPV vaccination uptake is lower, the
incidence remained stable over the period,
suggesting that the observed decrease is due to
HPV vaccination.
While the first indication of the clinical
impact of HPV vaccination has been shown by
the reduction in the incidence of GWs, the
impact on the incidence of cervical
abnormalities that can give rise to pre-
cancerous and cancerous cervical lesions is
suggestive of a long-term clinical impact.
Recent data, including two reviews, showing a
significant reduction in the incidence of
cervical abnormalities in countries where
4HPV was introduced early and with high
vaccine uptake have been published [54–59].
The studies presented in this review are
either analysis of national or very large
regional databases. Some of the studies
reported the vaccination status of the subjects
and so provided effectiveness data. Although
some of the studies included present the
classical potential limitations of database-
based and ecological studies, including
erroneous coding, underreporting to the
databases and potential biases, they allow a
pragmatic approach to continual assessment of
national vaccination programs. Another
possible limitation that should be
acknowledged is the potential publication bias,
which is inherent to literature reviews.
However, the authors feel, that as this is an
area of high interest, the studies are reported.
After the end of the literature search and the
submission of the paper we identified an
additional study that was not included in the
formal review but presented in the discussion.
Since GWs are not notifiable diseases in all
26 Adv Ther (2015) 32:10–30
countries, dedicated surveillance programs have
not been implemented as they have been for
some diseases, such as invasive pneumococcal
diseases and influenza [60].
Despite their limitations, these results show
that 4HPV vaccination programs have the
potential to significantly reduce the burden
associated with GWs. Some models, based on
data from clinical trials and estimates for the
high burden of GWs to healthcare systems,
predict that vaccination costs can be offset by
reductions in GW disease costs [10]. The studies
in this overview can be used to verify the
reliability of published models on the timing
of reduction of such diseases and the possible
impact of vaccination programs in countries
with no surveillance systems. In summary, the
data from these international studies (6
countries, 3 different continents) summarized
in this review give an encouraging view of the
early clinical impact of introducing 4HPV into
national vaccination programs.
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